11月12日盘前交易中,诺瓦瓦克斯医药(NVAX)股价大涨8.21%,引发市场关注。这与美国FDA近日做出的一项重要决定密切相关。
据悉,FDA解除了此前对诺瓦瓦克斯新冠流感联合疫苗和独立流感疫苗临床试验的限制。由于部分参与者在试验中出现不良反应,这两个疫苗项目的后期试验曾一度被叫停。不过,在诺瓦瓦克斯提供补充材料证明不良反应与试验疫苗无关后,FDA决定解除限制令。
业内人士指出,FDA这一决定相当于为诺瓦瓦克斯的新冠流感联合疫苗和独立流感疫苗未来商业化推广扫清了最后一个障碍。作为疫苗研发新秀,诺瓦瓦克斯已经引起了投资界的极大关注。FDA的利好消息显著提振了市场对该公司发展前景的信心,推动其股价在盘前交易中大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.